Statistics

Total Visits

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial77

File Visits

Downloads
VERSION EDITOR.pdf13

Select a period of time:

Number of views in the range

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial51

Number of downloads in the range

Downloads
VERSION EDITOR.pdf2

Views

Views
February 20251
March 202519
April 20252
May 20253
June 20257
July 202517
August 20252
Download CSV file
 untranslated
 untranslated

Number of downloads in the period of time

  • Downloads
  • February 2025
    0
  • March 2025
    0
  • April 2025
    1
  • May 2025
    0
  • June 2025
    0
  • July 2025
    0
  • August 2025
    1
  • Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore19
Brazil8
United States6
Hong Kong4
Mexico3
United Kingdom2
Germany2
Argentina1
Austria1
Barbados1
 

Top countries by downloads

Downloads
United States1
 

Top cities views

Views
Hong Kong4
Addis Ababa1
Barbacena1
Caxias do Sul1
Coronel Brandsen1
Council Bluffs1
Guadalajara1
Guanajuato City1
Jackson1
Lafayette1
 

Top cities by downloads

Downloads